Clairity just raised $43M in Series B funding, and it lands with the kind of force that makes an entire industry stop mid-sentence. When ACE Global Equity and Santé Ventures lead again, it is not nostalgia. It is conviction earned the hard way, through data that refuses to blink and a product that does exactly what most AI in healthcare only promises. The Breast Cancer Research Foundation stayed in the mix, backing Clairity the same way it has backed the work of Dr. Constance Lehman for years, and that continuity matters. Investors follow heat, but they stay for proof, and Clairity has stacked enough of it to power its own grid.
What Dr. Constance Lehman and CEO Jeffrey Luber have built is not another AI model hoping to decode a mammogram. Clairity Breast, FDA authorized under the name Allix5, is the first and only De Novo cleared platform that predicts a woman’s 5-year breast cancer risk from a standard 2D screening mammogram with calibrated precision. It reads the tissue like a second language and turns patterns invisible to radiologists into actionable risk scores that clinicians can trust. Millions of images trained the model. 77,000+ mammograms formed the foundation of its first validation. Another 120,000 across 10 US health systems proved the system could survive real-world gravity. AUC 0.72 is not a marketing number. It is a clinical one.
Clarity built its engine with intention, training across diverse racial and ethnic populations instead of the narrow datasets that shaped older risk models. The result is a platform that can identify women at 2 to 4x higher risk, including those with non-dense breasts who would have slipped through traditional screening frameworks. In a world where 85% of diagnosed women have no family history, image-only risk prediction is not a luxury. It is the new starting point.
Jeffrey Luber arrived as CEO in late 2024 with a resume built for this exact inflection point, from scaling diagnostic companies into commercial machines to securing the kind of clinical and regulatory traction that separates momentum from noise. Under his leadership, Clairity is moving into nationwide deployment across imaging centers, hospitals, and digital health channels, with reimbursement efforts already in motion. Clairity Breast 3D and Clairity Heart are in development, extending the same deep learning framework into 3D mammography and cardiovascular risk prediction.
When a company names itself Clairity, it invites scrutiny. After this round, the picture is sharper, the path is wider, and the signal is unmistakable. This is what it looks like when a technology built for early detection evolves into a platform built for prevention, and the market knows it.
Startups Startup Funding Venture Capital Series B AI AI Imaging Healthcare Health Tech Screening Tech Imaging Tech Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem
